NP / PA
Ado INC.
Ado INC. was paid $1.85M by Medicaid between Apr 2019 and Dec 2024, across 19 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 44% of everything it billed.
33Billing provider infoADO INC.
TAZEWELL, TN 37879
TAZEWELL, TN 37879
33aNPI1508334129assigned 11/13/2018
33bProvider typeFamily Nurse Practitioner
28Total paid$1.85M
24GClaims97,150
24DCodes billed19
24AFirst – last monthApr 2019 – Dec 2024
Compared with peers
Next to other Family Nurse Practitioner providers in Tennessee
Rank by total paid#10 of 687
Median peer was paid$15K
This provider vs. median127×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 2,303 | $55K | |
| 2020 | 5,431 | $98K | |
| 2021 | 23,274 | $371K | |
| 2022 | 26,335 | $447K | |
| 2023 | 20,986 | $456K | |
| 2024incomplete | 18,821 | $418K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 44% | 26,277 | 22,275 | $816K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 30% | 13,959 | 12,088 | $556K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 11% | 21,999 | 9,440 | $198K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 4.4% | 1,784 | 1,457 | $82K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.8% | 7,442 | 6,527 | $69K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 3.0% | 1,659 | 1,529 | $55K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.8% | 3,292 | 2,135 | $32K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 306 | 242 | $12K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 217 | 186 | $8K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 230 | 219 | $7K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 18 | 17 | $5K |
| 81001 | <1% | 968 | 829 | $2K |
7 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 58 | $1K |
| 36415 | Collection of venous blood by venipuncture | <1% | 755 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 959 | $447.17 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 21 | $163.53 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 97 | $150.34 |
| 99000 | <1% | 6,296 | $7.16 | |
| 99072 | 0% | 10,813 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARTIN, DANIEL (CEO)
Parent organizationADO INC.